ABBV Financials: AbbVie Inc AI Analysis



Financials

ABBV Financial

AbbVie Inc

$249.82

-0.35%

$-0.9

At close: Jun 26, 16:00:00 GMT-4

$249.82

Pre-market: Jun 29, 09:42:38 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$250.72

Open

$253.04

Day's Range

$249.82 - $253.04

52 week range

$181.73 - $249.82

Volume

487.5K

Avg.Volume

6.6M

Dividend yield

2.97%

EPS (TTM)

2.49

Market Cap

$441.3B

What is ABBV?

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	62,819	15,002	16,618	15,776	15,423	13,343
Revenue Growth (YoY)	10%	12%	10%	9%	7%	8%
Cost of Revenue	17,573	4,218	4,552	4,457	4,346	4,002
Gross Profit	45,246	10,784	12,066	11,319	11,077	9,341
Selling, General & Admin	14,295	3,578	3,895	3,569	3,253	3,293
Research & Development	9,501	2,472	2,579	2,319	2,131	2,067
Operating Expenses	23,555	6,050	6,257	5,888	5,360	5,360
Other Non Operating Income (Expenses)	-6,658	-2,306	-1,210	-503	-2,639	-1,441
Pretax Income	5,975	1,039	2,668	714	1,554	1,661
Income Tax Expense	2,334	342	853	526	613	372
Net Income	3,595	685	1,806	176	928	1,276
Net Income Growth	-13%	-46%	-5,744%	-89%	-32%	-6%
Shares Outstanding (Diluted)	1,774	1,774	1,776	1,772	1,771	1,772
Shares Change (YoY)	0%	0%	0%	0%	0%	0%
EPS (Diluted)	2.02	0.38	1.02	0.1	0.52	0.72
EPS Growth	-14%	-46%	-5,200%	-89%	-32%	-6%
Free Cash Flow	19,980	3,564	4,889	6,643	4,884	1,400
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	72.02%	71.88%	72.6%	71.74%	71.82%	70%
Operating Margin	34.52%	31.55%	34.95%	34.42%	37.06%	29.83%
Profit Margin	5.72%	4.56%	10.86%	1.11%	6.01%	9.56%
Free Cash Flow Margin	31.8%	23.75%	29.41%	42.1%	31.66%	10.49%
EBITDA	29,727	6,670	7,796	7,494	7,767	6,020
EBITDA Margin	47.32%	44.46%	46.91%	47.5%	50.35%	45.11%
D&A For EBITDA	8,036	1,936	1,987	2,063	2,050	2,039
EBIT	21,691	4,734	5,809	5,431	5,717	3,981
EBIT Margin	34.52%	31.55%	34.95%	34.42%	37.06%	29.83%
Effective Tax Rate	39.06%	32.91%	31.97%	73.66%	39.44%	22.39%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

62,819

15,002

16,618

15,776

15,423

13,343

Revenue Growth (YoY)

10%

12%

10%

Cost of Revenue

17,573

4,218

4,552

4,457

4,346

4,002

Gross Profit

45,246

10,784

12,066

11,319

11,077

9,341

Selling, General & Admin

14,295

3,578

3,895

3,569

3,253

3,293

Research & Development

9,501

2,472

2,579

2,319

2,131

2,067

Operating Expenses

23,555

6,050

6,257

5,888

5,360

Other Non Operating Income (Expenses)

-6,658

-2,306

-1,210

-503

-2,639

-1,441

Pretax Income

5,975

1,039

2,668

714

1,554

1,661

Income Tax Expense

2,334

342

853

526

613

372

Net Income

3,595

685

1,806

176

928

1,276

Net Income Growth

-13%

-46%

-5,744%

-89%

-32%

-6%

Shares Outstanding (Diluted)

1,774

1,776

1,772

1,771

1,772

Shares Change (YoY)

EPS (Diluted)

2.02

0.38

1.02

0.1

0.52

0.72

EPS Growth

-14%

-46%

-5,200%

-89%

-32%

-6%

Free Cash Flow

19,980

3,564

4,889

6,643

4,884

1,400

Free Cash Flow Per Share

Gross Margin

72.02%

71.88%

72.6%

71.74%

71.82%

70%

Operating Margin

34.52%

31.55%

34.95%

34.42%

37.06%

29.83%

Profit Margin

5.72%

4.56%

10.86%

1.11%

6.01%

9.56%

Free Cash Flow Margin

31.8%

23.75%

29.41%

42.1%

31.66%

10.49%

EBITDA

29,727

6,670

7,796

7,494

7,767

6,020

EBITDA Margin

47.32%

44.46%

46.91%

47.5%

50.35%

45.11%

D&A For EBITDA

8,036

1,936

1,987

2,063

2,050

2,039

EBIT

21,691

4,734

5,809

5,431

5,717

3,981

EBIT Margin

34.52%

31.55%

34.95%

34.42%

37.06%

29.83%

Effective Tax Rate

39.06%

32.91%

31.97%

73.66%

39.44%

22.39%

Follow-Up Questions

What are AbbVie Inc's key financial statements?



According to the latest financial statement (Form-10K), AbbVie Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for ABBV?



AbbVie Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is AbbVie Inc's revenue broken down by segment or geography?



AbbVie Inc largest revenue segment is Immunology, at a revenue of 30,406,000,000 in the most earnings release.For geography, United States is the primary market for AbbVie Inc, at a revenue of 46,603,000,000.

Is AbbVie Inc profitable?



no, according to the latest financial statements, AbbVie Inc has a net loss of $0

Does AbbVie Inc have any liabilities?



no, AbbVie Inc has liability of 0

How many outstanding shares for AbbVie Inc?



AbbVie Inc has a total outstanding shares of 0

AbbVie Inc (ABBV) Financial

ABBV Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is ABBV?

AbbVie Inc (ABBV) Financial

ABBV Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is ABBV?

ABBV Income

Follow-Up Questions

What are AbbVie Inc's key financial statements?

What are the key financial ratios for ABBV?

How is AbbVie Inc's revenue broken down by segment or geography?

Is AbbVie Inc profitable?

Does AbbVie Inc have any liabilities?

How many outstanding shares for AbbVie Inc?